SCM
TARS icon

Sterling Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Sterling Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.25K Sell
147
-109
-43% -$6.96K ﹤0.01% 2261
2026
Q1 		$18K Buy
256
+3
+1% +$210 ﹤0.01% 2071
2025
Q4 		$20.7K Buy
253
+158
+166% +$11.8K ﹤0.01% 2207
2025
Q3 		$5.65K Buy
95
+1
+1% +$49 ﹤0.01% 2735
2025
Q2 		$3.81K Buy
94
+56
+147% +$2.52K ﹤0.01% 2659
2025
Q1 		$1.95K Hold
38
– – ﹤0.01% 2616
2024
Q4 		$2.1K Hold
38
– – ﹤0.01% 2772
2024
Q3 		$1.25K Buy
+38
New +$1.07K ﹤0.01% 2416

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sterling Capital Management's TARS Position: Q2 2026 in Review

Sterling Capital Management reduced its Tarsus Pharmaceuticals (TARS) stake by 43% in Q2 2026, selling an estimated $6.96K and leaving 147 shares worth $9.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2261.

Sterling Capital Management first reported a position in TARS in Q3 2024 and has held it in 8 quarters since. The position peaked at $20.7K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Sterling Capital Management held 147 shares of Tarsus Pharmaceuticals worth $9.25K as of Q2 2026.
  • Sterling Capital Management sold 109 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $6.96K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2261 holding.
  • Sterling Capital Management first reported a position in Tarsus Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Tarsus Pharmaceuticals position peaked at $20.7K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.